Review questions family constellation therapy as a supplement to depression treatment amid limited evidence

A recent review in Frontiers in Psychiatry scrutinises the potential integration of family constellation therapy with antidepressant medication for depression, highlighting the lack of robust evidence and calling for further research before its routine use.

A new review in Frontiers in Psychiatry argues that depression treatment may benefit from pairing antidepressant medication with family constellation therapy, but it also makes clear that the idea remains unproven in practice. The authors say standard drugs such as selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors remain important for easing symptoms, yet their slow onset, variable response and side effects leave many patients needing more than medication alone.

The review places that argument in the broader context of depression care, noting that combined treatment approaches already have support when medication is paired with established psychotherapies. Reuters-style evidence reviews have long found that depression is shaped by biological, psychological and social pressures at the same time, and the paper uses that biopsychosocial model to justify looking beyond neurotransmitters alone. It also highlights research linking depression to chronic stress, loneliness, discrimination, family conflict and low support, especially where those pressures are embedded in the home.

The family environment, the authors contend, can be a powerful driver of risk across generations. They point to studies connecting parental psychopathology, childhood maltreatment, high conflict, low cohesion and emotional over-involvement with later depression. Other research they cite suggests that family stress may even leave biological traces, including inflammatory changes and epigenetic shifts in stress-regulation genes, although the review is careful to note that these findings do not validate the more speculative ideas behind family constellation therapy itself.

Family constellation therapy, first developed by Bert Hellinger, is described as a brief group intervention built around the notion that hidden family loyalties and unresolved trauma shape mental health. In practice, clients choose group members to represent relatives and then observe how those representatives are placed and how they respond. The therapy’s supporters say this can surface buried grief, exclusion and distorted family roles, but the review stresses that its core concepts, including “orders of love” and “representative perception”, sit outside mainstream evidence-based psychology.

The evidence base, the authors say, is thin. Earlier reviews have reported only modest to moderate effects for broad psychological symptoms, and a 2024 randomised trial of a pandemic-adjusted version of the therapy found only small gains that largely faded by six months. A separate 2026 meta-analysis of family constellations across conditions concluded that there is no reliable evidence supporting its use, although that paper is still a preprint and has not yet been peer reviewed. Taken together, the literature suggests possible signals of benefit, but not enough to justify routine use, particularly for vulnerable patients.

That caution also shapes the paper’s view of combining the therapy with medication. The authors say the case for integration is theoretical, not tested: no randomised trial has directly compared medication plus family constellation therapy with either treatment alone. While combined treatment has shown clear advantages when medication is paired with proven psychotherapies such as cognitive behavioural therapy or interpersonal therapy, the review says those findings cannot simply be transferred to family constellation work. It calls for manualised protocols, better training and properly designed trials before clinicians consider the approach for treatment-resistant depression or complex family trauma.